Leads for antitubercular compounds from kinase inhibitor library screens
Discovering new drugs to treat tuberculosis more efficiently and to overcome multidrug resistance is a world health priority. To find antimycobacterial scaffolds, we screened a kinase inhibitor library of more than 12,000 compounds using an integrated strategy involving whole cell-based assays with Corynebacterium glutamicum and Mycobacterium tuberculosis, and a target-based assay with the protein kinase PknA. Seventeen "hits" came from the whole cell-based screening approach, from which three displayed minimal inhibitory concentrations (MIC) against M. tuberculosis below 10μM and were non-mutagenic and non-cytotoxic. Two of these hits were specific for M. tuberculosis versus C. glutamicum and none of them was found to inhibit the essential serine/threonine protein kinases, PknA and PknB present in both bacteria. One of the most active hits, VI-18469, had a benzoquinoxaline pharmacophore while another, VI-9376, is structurally related to a new class of antimycobacterial agents, the benzothiazinones (BTZ). Like the BTZ, VI-9376 was shown to act on the essential enzyme decaprenylphosphoryl-β-D-ribose 2'-epimerase, DprE1, required for arabinan synthesis.
Keywords: Tuberculosis ; Screening ; Kinase inhibitor ; Quinoxaline ; Serine/threonine protein Kinase (STPK) ; DprE1 ; Mycobacterium-Tuberculosis ; Pathogenic Mycobacteria ; Protein-Kinases ; Drug Discovery ; Pknb ; Identification ; Macrophages ; Clofazimine ; Candidate ; Resistant
Record created on 2010-11-08, modified on 2016-08-08